The GLP-1 saga is only getting juicier and messier
The FDA warned Novo Nordisk about failing to disclose risks and report deaths linked to semaglutide, while GLP-1 drugs surge in popularity for diabetes and weight loss despite unapproved market alternatives.
The GLP-1 saga is only getting juicier and messier
The FDA warned Novo Nordisk about failing to disclose risks and report deaths linked to semaglutide, while GLP-1 drugs surge in popularity for diabetes and weight loss despite unapproved market alternatives.
Luke O'Neill: Weight-loss drugs have been linked to sudden blindness, so how worried should you be?
The weight loss jabs Ozempic, Mounjaro and Wegovy - a type of medicine containing semaglutide - are increasingly being seen as a medical wonder of the age. They bring great benefits to people with diabetes and obesity.
Can GLP-1 drugs treat addiction? A new study hints at their potential
GLP-1 medications reduce risk of all substance use disorders including alcohol, nicotine, cannabis, opioids, and cocaine, while decreasing drug-related overdoses and deaths.